Myelodysplastic Syndromes Clinical Trial
— ONTIMEOfficial title:
Phase III MultiCenter Randomized Controlled Study to Assess Efficacy and Safety of ON 01910.Na 72-Hr Continuous IV Infusion in MDS Patients With Excess Blasts Relapsing After or Refractory to or Intolerant to Azacitidine or Decitabine
NCT number | NCT01241500 |
Other study ID # | 04-21 |
Secondary ID | |
Status | Completed |
Phase | Phase 3 |
First received | |
Last updated | |
Start date | November 2010 |
Est. completion date | October 3, 2018 |
Verified date | July 2018 |
Source | Onconova Therapeutics, Inc. |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The primary objective of this study is to compare overall survival (OS) in patients receiving ON 01910.Na + best supportive care (BSC) to OS of patients receiving BSC in a population of patients with myelodysplastic syndrome (MDS) with excess blasts (5% to 30% bone marrow blasts) who have failed azacitidine or decitabine treatment. This patient population has no available therapy and a short life expectancy (approximately 4 months). The high level of bone marrow activity of ON 01910.Na documented in Phase 1 and 2 studies has the potential to delay substantially the transition of MDS to Acute Myeloid Leukemia(AML), a very significant and severe complication, which shortens survival of these MDS patients.
Status | Completed |
Enrollment | 299 |
Est. completion date | October 3, 2018 |
Est. primary completion date | October 3, 2018 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - MDS diagnosis confirmed within 6 weeks prior to entry according to WHO or FAB classification - MDS classified as follows, according to WHO and FAB classification: - RAEB-1 (5% - 9% BM blasts) - RAEB-2 (10% - 19% BM blasts) - CMML (10% - 20% BM blasts) and WBC < 13,000/µL - RAEB-t (20% - 30% BM blasts), with following criteria: - o WBC < 25 x 10E9/L at entry - o Stable WBC at least 4 weeks prior to entry and not requiring intervention for WBC control with hydroxyurea, chemotherapy, or leukopheresis. - At least one cytopenia (ANC < 1800/µL or platelet count < 100,000/µL or hemoglobin <10 g/dL) - Progression according to 2006 International Working Group (IWG) criteria any time after start of azacitidine or decitabine during past 2 years; or failure to achieve complete or partial response or hematological improvement (according to 2006 IWG) after at least six 4-week cycles of azacitidine or four 6-week cycles of decitabine during past 2 years; or relapse after initial complete or partial response or hematological improvement (according to 2006 IWG criteria) observed after at least six 4-week cycles of azacitidine or four 6-week cycles of decitabine during past 2 years; or, intolerance to azacitidine or decitabine defined by drug-related =Grade 3 liver or renal toxicity leading to discontinuation during the past 2 years. - Did not respond to, relapsed after, not eligible for, or opted not to do bone marrow transplantation - Off other MDS treatments for at least 4 weeks; Filgrastim (G-CSF) and erythropoietin allowed before and during the study as clinically indicated. - No need for induction chemotherapy - ECOG status 0, 1 or 2 - Willing to adhere to protocol prohibitions and restrictions - Patient (or a legally authorized representative) must sign informed consent form to indicate patient's understanding study's purpose and procedures and willingness to participate Exclusion Criteria: - Anemia due to factors other than MDS (including hemolysis or gastrointestinal bleeding) unless stabilized for 1 week after RBC transfusion. - Any active malignancy within the past year, except basal cell or squamous cell skin cancer or carcinoma in situ of the cervix or breast - Uncontrolled intercurrent illness including, but not limited to, symptomatic congestive heart failure, unstable angina pectoris, or cardiac arrhythmia - Active infection not adequately responding to appropriate therapy - Total bilirubin =1.5 mg/dL not related to hemolysis or Gilbert's disease. - Alanine transaminase (ALT)/aspartate transaminase (AST) =2.5 x upper limit of normal (ULN) - Serum creatinine =2.0 mg/dL - Ascites requiring active medical management including paracentesis, or hyponatremia (defined as serum sodium value of <130 mEq/L) - Pregnant or lactating females - Patients unwilling to follow strict contraception requirements (including condom use for males with sexual partners, and for females: prescription oral contraceptives [birth control pills], contraceptive injections, intrauterine device, double-barrier method [spermicidal jelly or foam with condoms or diaphragm], contraceptive patch, or surgical sterilization) before entry and throughout the study - Females with reproductive potential who do not have a negative urine beta-human chorionic gonadotropin pregnancy test at screening - Major surgery without full recovery or major surgery within 3 weeks of ON 01910.Na treatment start - Uncontrolled hypertension (defined as systolic pressure =160 mmHg and/or diastolic pressure =110 mmHg) - New onset seizures (within 3 months prior to first dose of ON 01910.Na) or poorly controlled seizures - Any other concurrent investigational agent or chemotherapy, radiotherapy, or immunotherapy - Prior treatment with low-dose cytarabine during past 2 years Investigational therapy within 4 weeks of starting ON 01910.Na - Psychiatric illness or social situation that limits the patient's ability to tolerate and/or comply with study requirements |
Country | Name | City | State |
---|---|---|---|
Belgium | Ziekenhuis Netwerk Antwerpen | Antwerp | |
Belgium | Universitair Ziekenhuis Gent | Gent | |
Belgium | H. Hartziekenhuis Roeselare-Menen vzw | Roeselare | West-vlaanderen |
Belgium | CHU de Mont-Godinne | Yvoir | |
France | CHU Angers Service de Medecine D - Maladies du Sang | Angers | |
France | CHU Avignon Centre Hospitalier Henri Dufaut | Avignon | |
France | Hôpital Avicenne Hématologie Clinique | Bobigny | |
France | CHU Caen Hématologie Clinique | Caen | |
France | CHU Estaing Service d'hématologie | Clermont-Ferrand | |
France | CHU Lille Hôpital Claude Huriez | Lille | |
France | CHU Limoges Hopital Dupuytren | Limoges | |
France | Institute Paoli Calmettes | Marseille | |
France | Hôpital de L'archet I | Nice | |
France | Hôpital Saint-Antoine | Paris | |
France | Hôtel Dieu Sce Hématologie Clinique | Paris | |
France | CHU Perpignan Centre Hospitalier Hôpital Saint-Jean | Perpignan | |
France | CRLCC Henri Becquerel | Rouen | |
France | Chu-Strasbourg-Hopital Civil | Strasbourg | |
France | Hôpital Purpan | Toulouse | |
Germany | Universitätsklinikum Bonn | Bonn | Nordrhein-westfalen |
Germany | Universitätsklinikum Dresden | Dresden | |
Germany | Heinrich-Heine-Universität Düsseldorf | Düsseldorf | |
Germany | Klinikum der Johann Wolfgang-Goethe-Universität | Frankfurt am Main | |
Germany | Universitätsklinikum Hamburg-Eppendorf | Hamburg | |
Germany | Universitätsklinikum zu Köln | Köln | |
Germany | Universitätsmedizin Mannheim | Mannheim | |
Germany | Johannes-Wesling-Klinikum Minden | Minden | |
Germany | Klinikum Rechts der Isar der Technischen Universität München | München | |
Germany | Universitätsklinikum Ulm | Ulm | |
Italy | Azienda Ospedaliera Santi Antonio e Biagio e Cesare Arrigo | Alessandria | |
Italy | Azienda Ospedaliero-Universitaria di Bologa Policlinico S. Orsola-Malpighi | Bologna | |
Italy | Azienda Ospedaliera-Universitairia Vittorio Emanuele-Ferrarotto-Santo Bambino | Catania | |
Italy | Azienda Ospedaliera Universitaria Careggi di Firenze | Firenze | |
Italy | Azienda Ospedaliera Universitaria San Martino | Genova | |
Italy | Azienda Osperdaliera Universitaria Maggiore della Carità | Novara | |
Italy | Università degli Studi La Sapienza | Roma | |
Italy | Azienda Ospedaliera Universitaria Senese Policlinico Santa Maria alle Scotte | Siena | SI |
Italy | Azienda Ospedaliero Universitaria San Giovanni Battista di Torino | Torino | |
Spain | Hospital Universitario La Paz | Madrid | |
Spain | Hospital Universitario La Princesa | Madrid | |
Spain | Hospital Clínico Universitario Virgen de la Victoria | Málaga | |
Spain | Hospital Universitario Central de Asturias | Oviedo | Asturias |
Spain | Hospital Universitario Son Espases | Palma de Mallorca | |
Spain | Hospital Clínico Universitario de Salamanca | Salamanca | |
Spain | Hospital Clínico Universitario de Valencia | Valencia | |
Spain | Hospital Universitari i Politècnic La Fe | Valencia | |
United States | University of Michigan Comprehensive Cancer Center | Ann Arbor | Michigan |
United States | Emory University Winship Cancer Institute | Atlanta | Georgia |
United States | Johns Hopkins Hospital | Baltimore | Maryland |
United States | University of Maryland Greenebaum Cancer Center | Baltimore | Maryland |
United States | Mary Bird Perkins Cancer Center | Baton Rouge | Louisiana |
United States | Dana-Farber Cancer Institute | Boston | Massachusetts |
United States | Albert Einstein College of Medicine | Bronx | New York |
United States | Medical University of South Carolina | Charleston | South Carolina |
United States | Rush University Medical Center | Chicago | Illinois |
United States | University of Chicago Medical Center | Chicago | Illinois |
United States | Cleveland Clinic | Cleveland | Ohio |
United States | University of Texas Southwestern Medical Center at Dallas | Dallas | Texas |
United States | North Shore Medical Center | Evanston | Illinois |
United States | Bon Secours St. Francois Health System | Greenville | South Carolina |
United States | Hackensack University Medical Center | Hackensack | New Jersey |
United States | University of Texas M. D. Anderson Cancer Center | Houston | Texas |
United States | Integrated Community Oncology Network | Jacksonville | Florida |
United States | University of California San Diego Moores Cancer Center | La Jolla | California |
United States | North Shore - LIJ Health System | Lake Success | New York |
United States | Cardinal Bernardin Cancer Center | Maywood | Illinois |
United States | Innovative Medical Research of South Florida, Inc. | Miami | Florida |
United States | Mount Sinai Comprehensive Cancer Centers | Miami Beach | Florida |
United States | Medical College of Wisconsin | Milwaukee | Wisconsin |
United States | Yale Cancer Center | New Haven | Connecticut |
United States | Mount Sinai Medical Center | New York | New York |
United States | Weill Cornell Medical College | New York | New York |
United States | University of Oklahoma Health Science Center | Oklahoma City | Oklahoma |
United States | Woodlands Medical Specialists | Pensacola | Florida |
United States | University of Pennsylvania Health System | Philadelphia | Pennsylvania |
United States | Mayo Clinic | Rochester | Minnesota |
United States | Cancer Care Centers of South Texas | San Antonio | Texas |
United States | Virginia G. Piper Cancer Center | Scottsdale | Arizona |
United States | Fred Hutchinson Cancer Research Center | Seattle | Washington |
United States | Edward H. Kaplan MD & Associates | Skokie | Illinois |
United States | Providence Cancer Center | Southfield | Michigan |
United States | Stanford Cancer Center | Stanford | California |
United States | Martin Memorial Cancer Center | Stuart | Florida |
United States | Overlook Hospital | Summit | New Jersey |
United States | Georgetown University Hospital | Washington | District of Columbia |
United States | Cleveland Clinic Florida | Weston | Florida |
United States | University of Kansas Medical Center | Westwood | Kansas |
Lead Sponsor | Collaborator |
---|---|
Onconova Therapeutics, Inc. | The Leukemia and Lymphoma Society |
United States, Belgium, France, Germany, Italy, Spain,
Al-Kali A. Relationship of bone marrow blast (BMBL) response to overall survival (OS) in a multicenter study of rigosertib (Rigo) in patients (pts) with myelodysplastic syndrome (MDS) with excess blasts progressing on or after treatment with a hypomethyla
Athuluri-Divakar SK, Vasquez-Del Carpio R, Dutta K, Baker SJ, Cosenza SC, Basu I, Gupta YK, Reddy MV, Ueno L, Hart JR, Vogt PK, Mulholland D, Guha C, Aggarwal AK, Reddy EP. A Small Molecule RAS-Mimetic Disrupts RAS Association with Effector Proteins to Block Signaling. Cell. 2016 Apr 21;165(3):643-55. doi: 10.1016/j.cell.2016.03.045. — View Citation
Garcia-Manero G, Fenaux P, Al-Kali A, Baer MR, Sekeres MA, Roboz GJ, Gaidano G, Scott BL, Greenberg P, Platzbecker U, Steensma DP, Kambhampati S, Kreuzer KA, Godley LA, Atallah E, Collins R Jr, Kantarjian H, Jabbour E, Wilhelm FE, Azarnia N, Silverman LR; — View Citation
Garcia-Manero G, Fenaux P. Comprehensive Analysis of Safety: Rigosertib in 557 Patients with Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML). Blood Dec 2016, 128 (22) 2011; ASH 2016.
Navada SC, Silverman LR. The safety and efficacy of rigosertib in the treatment of myelodysplastic syndromes. Expert Rev Anticancer Ther. 2016 Aug;16(8):805-10. doi: 10.1080/14737140.2016.1209413. Epub 2016 Jul 15. Review. — View Citation
Seetharam M, Fan AC, Tran M, Xu L, Renschler JP, Felsher DW, Sridhar K, Wilhelm F, Greenberg PL. Treatment of higher risk myelodysplastic syndrome patients unresponsive to hypomethylating agents with ON 01910.Na. Leuk Res. 2012 Jan;36(1):98-103. doi: 10.1016/j.leukres.2011.08.022. Epub 2011 Sep 14. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Overall survival | Overall survival (OS) is defined as the time from randomization to death from any cause. All patients will be followed until death or progression, even if they have discontinued treatment for whatever cause. Patients lost to follow-up will be censored at the time last known alive. The OS primary analysis will compare the active ON 01910.Na regimen to BSC once a total number of 223 deaths has been reached. | Up to 18 months | |
Secondary | Overall response (complete and partial remission) according to 2006 IWG criteria | Compare the BSC + ON 01910.Na group to the BSC group with respect to changes in bone marrow myeloblasts, hemoglobin, peripheral neutrophils, platelets and blasts. | Changes measured at Week 4 from Baseline and every 8 Weeks thereafter | |
Secondary | Complete bone marrow response according to 2006 IWG criteria | Compare the BSC + ON 01910.Na group to the BSC group with respect to changes in bone marrow myeloblasts. | Changes measured at Week 4 from Baseline and every 8 Weeks thereafter | |
Secondary | Hematological improvements according to 2006 IWG criteria | Compare the BSC + ON 01910.Na group to the BSC group with respect to in absolute neutrophil count (ANC), platelet count, and erythroid responses. | Weekly | |
Secondary | Scores of Quality of Life Questionnaire | Compare the BSC + ON 01910.Na group to the BSC group with respect to scores of Quality-of-life (QOL)(using the European Organization for Research and Treatment of Cancer [EORTC] Quality of Life Questionnaire [QLQ]-C30 version 3. | Measured at Baseline and every 4 Weeks | |
Secondary | Adverse events | Record adverse events according to CTCAE v4. | Weekly | |
Secondary | Change in Aneuploidy | Improvements of cytogenetics as evaluated by the change in aneuploidy in bone marrow according to 2006 IWG criteria. | Baseline and, only if abnormal at Baseline, Week 4 and every 8 Weeks thereafter | |
Secondary | Transition time to AML | Transition time to AML: Defined for RAEB-1 and RAEB-2 MDS and chronic myelomonocytic leukemia (CMML) patients (with BM blasts from 10% to 20% for CMML) by an increase of at least 50% BM blasts and more than 20% BM blasts; Defined for RAEB-t by an increase of at least 50% BM blasts. | Measured at Week 4 from date of randomization and every 8 Weeks thereafter | |
Secondary | Incidence of infections and bleeding episodes. | Incidence of infections (treated with intravenous antimicrobials) and bleeding episodes. | Every 4 Weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05400122 -
Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer
|
Phase 1 | |
Terminated |
NCT04313881 -
Magrolimab + Azacitidine Versus Azacitidine + Placebo in Untreated Participants With Myelodysplastic Syndrome (MDS)
|
Phase 3 | |
Recruiting |
NCT05088356 -
Reduced Intensity Allogeneic HCT in Advanced Hematologic Malignancies w/T-Cell Depleted Graft
|
Phase 1 | |
Recruiting |
NCT04003220 -
Idiopathic Chronic Thrombocytopenia of Undetermined Significance : Pathogenesis and Biomarker
|
||
Completed |
NCT02916979 -
Myeloid-Derived Suppressor Cells and Checkpoint Immune Regulators' Expression in Allogeneic SCT Using FluBuATG
|
Phase 1 | |
Active, not recruiting |
NCT03755414 -
Study of Itacitinib for the Prophylaxis of Graft-Versus-Host Disease and Cytokine Release Syndrome After T-cell Replete Haploidentical Peripheral Blood Hematopoietic Cell Transplantation
|
Phase 1 | |
Completed |
NCT00003270 -
Chemotherapy, Radiation Therapy, and Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer
|
Phase 2 | |
Recruiting |
NCT04904588 -
HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation With Post-Transplantation Cyclophosphamide
|
Phase 2 | |
Terminated |
NCT04866056 -
Jaktinib and Azacitidine In Treating Patients With MDS With MF or MDS/MPN With MF.
|
Phase 1/Phase 2 | |
Recruiting |
NCT04701229 -
Haploinsufficiency of the RBM22 and SLU7 Genes in Del(5q) Myelodysplastic Syndromes
|
||
Suspended |
NCT04485065 -
Safety and Efficacy of IBI188 With Azacitidine in Subjects With Newly Diagnosed Higher Risk MDS
|
Phase 1 | |
Recruiting |
NCT04174547 -
An European Platform for Translational Research in Myelodysplastic Syndromes
|
||
Enrolling by invitation |
NCT04093570 -
A Study for Participants Who Participated in Prior Clinical Studies of ASTX727 (Standard Dose), With a Food Effect Substudy at Select Study Centers
|
Phase 2 | |
Completed |
NCT02508870 -
A Study of Atezolizumab Administered Alone or in Combination With Azacitidine in Participants With Myelodysplastic Syndromes
|
Phase 1 | |
Completed |
NCT04543305 -
A Study of PRT1419 in Patients With Relapsed/Refractory Hematologic Malignancies
|
Phase 1 | |
Recruiting |
NCT05384691 -
Efficacy of Luspatercept in ESA-naive LR-MDS Patients With or Without Ring Sideroblasts Who do Not Require Transfusions
|
Phase 2 | |
Recruiting |
NCT05365035 -
A Phase II Study of Cladribine and Low Dose Cytarabine in Combination With Venetoclax, Alternating With Azacitidine and Venetoclax, in Patients With Higher-risk Myeloproliferative Chronic Myelomonocytic Leukemia or Higher-risk Myelodysplastic Syndromes With Excess Blasts
|
Phase 2 | |
Recruiting |
NCT06008405 -
Clinical Trial Evaluating the Safety of the TQB2928 Injection Combination Therapy
|
Phase 1 | |
Not yet recruiting |
NCT05969821 -
Clonal Hematopoiesis of Immunological Significance
|
||
Withdrawn |
NCT05170828 -
Cryopreserved MMUD BM With PTCy for Hematologic Malignancies
|
Phase 1 |